News Releases

ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2018

REDWOOD CITY, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a long-acting PEGylated form of recombinant human Interleukin-10 (IL-10), have been accepted for poster presentation at the upcoming 2018 ASCO Annual Meeting, taking place June 1-5, 2018 at McCormick Place, in Chicago, Illinois.

Title:    Overall Survival of PEGylated Pegilodecakin with 5-FU/LV and Oxaliplatin (FOLFOX) in Metastatic Pancreatic Adenocarcinoma (PDAC).

Title:    Responses and Durability in NSCLC Treated with Pegilodecakin and anti-PD-1

Title:    Pegilodecakin with Nivolumab (nivo) or pembrolizumab (pembro) in Patients with Metastatic Renal Cell Carcinoma (RCC)

Additional details on the ASCO poster presentations will be announced on May 16, 2018 at 5:00 pm Eastern Time.

About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types.  The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients.  ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12).  For more information, please visit

Forward-Looking Statements
This release includes forward-looking statements. All statements other than statements of historical facts, including the statements about future clinical milestones of AM0010 or our other product candidates, the indications we intend to pursue and our possible clinical or other business strategies, are forward-looking statements. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. These forward-looking statements are based on our management’s current beliefs and assumptions about future events and on information currently available to management.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.  These risks include, but are not limited to, risks and uncertainties related to: our limited operating history and historical losses, our liquidity to fund the development of AM0010 and our other product candidates through current and future milestones, our ability to raise additional funding to complete the development and any commercialization of our product candidates, our dependence on the success of our lead product candidate, AM0010, results from the clinical trials and pre-clinical studies of third parties working in immuno-oncology and our dependence on third parties in connection with our manufacturing, clinical trials and pre-clinical studies. Additional risks and uncertainties that could affect our future results are included in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K filed with the SEC on March 30, 2018, which is available on the SEC’s website at and our website at Additional information on potential risks will be made available in other filings that we make from time to time with the SEC. In addition, any forward-looking statements contained in this press release are based on assumptions that we believe to be reasonable as of this date. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

ARMO BioSciences, Inc.
Herb Cross, Chief Financial Officer

Dan Ferry
LifeSci Advisors, LLC

Primary Logo

Source: ARMO BioSciences